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Background: The activation of CD40 is essential 
for the development of humoral and cellular 
immune responses. 
Results: CD40 dimerizes through the extracellular 
region via the CRD1 and recombinant CRD1 
potentiates CD40L activity. 
Conclusion: CD40-CRD1 participates to 
dimerization and is required for efficient receptor 
expression. 
Significance: CD40 self-assembly modulates 
signalling, possibly by maintaining the receptor in 
a quiescent state. 
 
SUMARY 
The activation of CD40 on B cells, 
macrophages and dendritic cells by its ligand 
CD154 (CD40L) is essential for the 
development of humoral and cellular immune 
responses. CD40L and other TNF superfamily 
ligands are non-covalent homotrimers, but the 
form under which CD40 exists in the absence of 
ligand remains to be elucidated. Here we show 
that both cell surface-expressed and soluble 
CD40 self-assemble, most probably as non-
covalent dimers. The cysteine-rich domain 1 
(CRD1) of CD40 participated to dimerization 
and was also required for efficient receptor 
expression. Modelization of a CD40 dimer 
allowed the identification of lysine 29 in CRD1, 
whose mutation decreased CD40 self-
interaction without affecting expression or 
response to ligand. When expressed alone, 
recombinant CD40-CRD1 bound CD40 with a 
KD of 0.6 µM. This molecule triggered 
expression of maturation markers on human 
dendritic cells and potentiated CD40L activity. 
These results suggest that CD40 self-assembly 
modulates signalling, possibly by maintaining 
the receptor in a quiescent state. 
Ligand-induced oligomerization is an 
important process for activating cell-surface 
receptors like cytokine receptors, G-protein-
coupled receptors, protein-tyrosine kinase 
receptors, Toll-like receptors, and tumor necrosis 
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factor receptor superfamily members (TNFRSF) in 
a number of biological events [1,2]. TNF family 
ligands form non-covalent homotrimers that can 
bind three receptor molecules [3]. Although this 
ligand-receptor complex is generally accepted to 
be the minimal requirement for signalling, some 
members of the family are only efficiently 
triggered by at least two adjacent trimeric ligands 
[4,5]. The form under which ligand-free TNFRSF 
members exist is still not fully understood. Indeed 
unliganded TNFR1 crystallized as a parallel dimer 
[6,7] while cell-based experiments rather proposed 
that receptors may pre-assemble as trimers in the 
absence of ligand [8]. Interestingly, DcR3 
(TNFRSF6B) assembled as parallel dimers when 
crystallized alone, but as trimers when co-
crystallized with its ligand TL1A, each receptor in 
this trimeric form contacting a different ligand [9]. 
Thus, receptors may exist both as dimers or 
trimers depending on the context. Gathering more 
structural information on unliganded TNF 
receptors will help to better understand the 
mechanism of ligand-induced receptor signalling. 
The extracellular region of TNFRSF members 
is characterized by the presence of cysteine-rich 
domains (CRDs) which typically contain six 
cysteine residues engaged in the formation of three 
disulfide bonds. The number of CRDs in a given 
receptor usually varies from one to four [3]. 
TNFR1 and CD40 possess four CRDs, of which 
only CRD2 and 3 are directly involved in ligand 
binding. Crystallography of unliganded TNFR1 
(TNFRSF1A) [6] showed homo-dimerization in 
either parallel or antiparallel manners [7]. 
Antiparallel dimers associate through an interface 
that overlaps with CRD1 and 2, whereas parallel 
dimers associate mainly via CRD1 and leave 
ligand binding sites accessible. Cell-based studies 
identified a pre-ligand-binding assembly domain 
at the N-terminus of TNFR1 and 2 that is required 
for pre-assembly of TNFR complexes in a fully 
ligand-responsive conformation [8]. In any case, 
TNF receptors appear to exist as preformed 
complexes and not as monomeric receptors that 
would only oligomerize upon ligand binding. In 
line with these results, the CRD1 of Fas 
(TNFRSF6) was shown to be essential for the 
formation of homotypic, ligand-independent 
receptor complexes [10]. The situation is more 
complex for the TNF-related apoptosis-inducing 
ligand (TRAIL), another TNF family member that 
binds five different receptors: two fully functional 
death receptors, TRAIL-R1 (TNFRSF10A) and 
TRAIL-R2 (TNFRSF10B), two membrane bound 
“decoy” receptors, TRAIL-R3 (TNFRSF10C) and 
TRAIL-R4 (TNFRSF10D) and a soluble “decoy” 
receptor, OPG (TNFRSF11B). Decoy receptors 
inhibit cell death by competing for TRAIL 
binding. However, inhibition of TRAIL-induced 
apoptosis by TRAIL-R4 critically depends on its 
association with TRAIL-R2 via the N-terminal 
domain containing the first partial CRD of both 
receptors. Thus, in contrast to homotypic TNFR1 
or Fas complexes, TRAIL-R2 and TRAIL-R4 
form mixed complexes as a mean to regulate 
TRAIL-induced apoptosis [11]. 
The present study focuses on CD40 
(TNFRSF5). Engagement of CD40 by CD40L 
leads to CD40 clustering, recruitment of TNFR 
associated factors and activation, among others, of 
the transcription factor NF-κB [12,13]. CD40 is 
mainly expressed on professional antigen 
presenting cells i.e dendritic cells, macrophages 
and B cells [14], and its activation is essential for 
the development of humoral and cellular immune 
responses. Thus, selective blockade or activation 
of CD40 is of pharmacological interest. The 
crystal structure of CD40-CD40L was recently 
solved showing that CRD2 and CRD3 are both 
involved in CD40L binding [15]; however little is 
known about the function of CRD1 and CRD4. 
Here we show that CD40 exists as preformed, 
non-covalent dimers on the cell surface and that 
dimerization is dependent on the extracellular 
region. Mutation of K29 in CRD1 impaired CD40 
self-assembly. Recombinant CD40-CRD1 bound 
the extracellular domain of CD40 with a KD of 
about 0.6 µM and displayed an agonist-like 
activity on CD40-expressing cells such as human 
dendritic cells. Co-incubation of CD40-CRD1 
with CD40L potentiated the NF-κB response 
induced by CD40L alone, suggesting that CRD1 
interactions participate in CD40 signalling. These 
observations provide a novel mean to manipulate 
CD40 signalling. 
 
EXPERIMENTAL PROCEDURES 
Cell lines and reagents – Human embryonic 
kidney HEK293 cells were grown in RPMI 1640 
medium (Lonza, Basel) supplemented with 10% 
fetal calf serum and 5 µg/mL of penicillin and 
streptomycin. Anti-CD40 (clone C20) monoclonal 
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antibody from Santa Cruz Biotechnology (Santa 
Cruz, CA) and horse radish peroxydase-coupled 
anti-myc antibody from Life technologies 
(Carlsbad, CA) were used for western blot 
analysis. Two different CD40L (CD154) were 
used as indicated: muCD8-CD40L (Ancell, MN) 
and Mega-CD40L (Adipogen, CA). Antibodies for 
flow cytometry analysis were purchased from 
Becton-Dickinson (Franklin Lakes, NJ): Pacific 
blue CD14 and PerCp5.5 HLA-DR were used for 
monocyte purification control; PE-Cy7 CD86, 
PerCp5.5 HLA-DR and APC CD83 were used to 
follow monocyte-derived dendritic cell 
maturation. 
Molecular cross-linking at the cell surface - 
Approximately 2 x 107 HEK293 cells stably 
expressing CD40 or BJAB cells were washed 
three times with ice-cold PBS (pH 8) within the 
culture flask (HEK cells) or in 15 mL tubes (BJAB 
cells). BS3 cross-linker (Thermo scientific, 
Waltham, MA) was added at a final concentration 
of 3 mM for 1 h at 4°C. The reaction was 
quenched by addition of Tris at a final 
concentration of 20 mM for 15 minutes. Cells 
were then harvested and analyzed by western blot. 
Recombinant proteins - Myc-His-tagged CD40 
was produced in HEK293 cells using the 
mammalian expression vector pSectag2-Hy (Life 
technologies) and purified from cell culture 
supernatant by nickel affinity chromatography. 
The encoded mature protein sequence was 
DAAQPAMNS, followed by amino acids 20-193 
of human CD40 and the sequence 
QAAARGGPEQKLISEEDLNSAVDHHHHHH. 
The CRD1 of CD40 was expressed in E.coli BL21 
Rosseta-gami 2 using the expression vector 
pET22b+ (Merck KGaA, Darmstadt, Germany). 
The encoded protein sequence was 
MDIGINSDPNS, followed by amino acids 20-62 
of human CD40 and the sequence 
AAALEHHHHHH. Mutations K29A, K29E, 
C26Q or the triple mutation C37G/C38G/C41G 
were introduced by conventional molecular 
biology techniques. Bacteria were induced for 
production of the proteins at an OD 600 nm of 0.6 
with 0.5 mM isopropyl β-D-thiogalactoside for 16 
h at 20°C. Soluble periplasmic proteins were 
extracted and purified by nickel affinity 
chromatography as described in [16].  
Mass spectrometry - Prior to mass analysis, 
protein samples were dialyzed against 200 mM 
ammonium acetate on Amicon Ultra-4 centrifugal 
filter unit-10000NMWL (Millipore, Billerica, 
MA). Mass spectrometry was performed on an 
ESI-TOF mass spectrometer Q-TOF micro 
(Waters, MA). Purity and homogeneity were 
verified by mass analysis in denaturing conditions: 
the protein was diluted to a concentration of 0.3 
µM in water - acetonitrile (1:10, v/v) acidified 
with 1 % formic acid. 
In non-denaturing conditions, the mass 
measurement of the protein was performed in 50 
mM ammonium acetate with 10% isopropanol, to 
preserve the native conformation. The protein was 
injected at 2.0 µM. Clusters of Cs(n+1)In were 
used for the calibration of the extended masse 
range in the high m/z region. Mass data were 
acquired in the positive ion mode on the mass 
range 1000-10000 m/z. CD40 deglycosylation was 
performed using the deglycosylation mix from 
New England Biolabs (Ipswich, MA) following 
manufacturer instructions. 
Molecular modelling - All procedures were 
performed with Discovery Studio 2.5 software 
from Accelrys (San Diego, CA). The crystal 
structure of the ligand-free TNFR1 (PDB 1NCF) 
was used as template to build a model of dimeric 
CD40. The receptor monomer correspond to the 
crystal structure of the complex CD40-CD40L 
(PDB 3QD6). A fixed atom constraint was applied 
to both C-terminal residues and the dimeric CD40 
model was subjected to an initial minimization 
step (max 500), RMS gradient 0.1 kcal/mol by 
conjugated gradient; followed by a second 
minimization step (max 500), RMS gradient 
0.0001 kcal/mol by conjugated gradient. The 
structure was then submitted to a dynamic 
simulation including heating (2000 steps), 
equilibration (1000 steps) and production (1000 
steps) at 300 °K with a time step of 0.001 ps under 
a distance-dependent, dielectric constant, implicit 
solvent model. A negative intermolecular energy 
of -361.5 kcal/mol was obtained for the complex 
under these conditions. In silico mutation K29A 
produced an increase on the interaction energy to -
218.0 kcal/mol, indicating a less stable complex. 
All images were generated using PyMOL 
Molecular Graphics System, Version 1.0, 
Schrödinger, LLC. 
FRET experiments - CD40-ECFP, CD40-EYFP 
and the negative control ERBB2-EYFP c-terminal 
fusion proteins all contained the full length 
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receptor sequences. Mutations K29A and K29E 
were introduced by site directed mutagenesis. 
Experiments were performed using a LSRII (BD 
Biosciences) flow cytometer instrument. EYFP 
signal was recorded using the 488 nm laser with a 
530/30 filter, ECFP signal was recorded using the 
405 nm laser with a 450/50 filter and FRET signal 
was recorded using the 405 nm laser with a 585/42 
filter. For each condition we evaluated a minimum 
of ten thousand -ECFP -EYFP double positive 
cells. HEK293 cells where transiently transfected 
with ECFP and EYFP fusion receptors and 
analyzed at 16 h post-transfection. Positive FRET 
cells were gated using an ECFP-EYFP fusion 
protein as positive control and a co-transfection of 
EFCP and EYFP as negative control according to 
[17]. 
Surface plasmon resonance - The BIACORE® 
3000 system, sensor chip CM5, surfactant P20, 
amine coupling kit containing N-
hydroxysuccinimide and N-Ethyl-N’-
dimethylaminopropyl carbodiimide, and 
ethanolamine were from BIACORE (Uppsala, 
Sweden). Biosensor assays were performed with 
HBS-EP buffer as running buffer (10 mM HEPES, 
150 mM sodium chloride, 3 mM EDTA 0.005% 
surfactant P20, pH 7.4). The low carboxylated 
dextran matrix (B1) was activated with 35 µL of a 
mixture 0.2 M N-ethyl-N-dimethylaminopropyl 
carbodiimide and 0.05 M N-hydroxysuccinimide 
at 5 µL/min. The anti-myc antibody (Life 
technologies) was immobilized with the standard 
BIACORE protocol at ~2000 RU per channel. 
Soluble CD40-myc tag fusion protein was injected 
for 30 sec, then increasing concentrations of 
recombinant CRD1 were injected for 2 min, 
followed by a dissociation phase of 3 min at a flow 
rate of 30 µL/min. All dilutions were performed in 
running buffer. The sensor chip surface was 
regenerated after each experiment by injecting 20 
µL of 3 M MgCl2. The kinetic parameters were 
calculated using the BIAeval 4.1 software. 
Analysis was performed using the simple 
Langmuir binding model. The specific binding 
profiles were obtained after subtracting the 
response signal from the control anti-myc antibody 
alone channel and from blank-buffer injection. 
The fitting to each model was judged by the chi 
square (χ2) value and randomness of residue 
distribution compared to the theoretical model. 
Active concentration was determined under mass 
transfer condition where the slope of the curves is 
directly correlated with the active concentration of 
the protein [18]. 
Luciferase reporter assay - HEK293 cells 
stably expressing either wt CD40 or CD40-K29A 
were cultured in 24 well plates at 3x105 cell/mL. 
After 24 h cells were transfected with control 
luciferase vectors or promoter specific luciferase 
reporter vectors (Panomics, Fremont, CA), using 
FuGene6 transfection reagent (Roche, Basel). 
Reporter luciferase assays were performed for 
STAT3, AP1, CRE, NF-κB and SRE that all are 
CD40L-activated transcription factors. After 24h, 
cells were treated with CD40L or a recombinant 
CD40-CRD1 protein at the indicated 
concentrations in the presence of 20 µg/mL of 
polymyxin B (Fluka, St. Louis, MO). After 16 h 
cells were lysed and luciferase activity was 
determined using a Wallac Victor2 1420 multilabel 
counter (PerkinElmer, Waltham, MA) according 
to instructions of the Promega luciferase assay 
system. Dual luciferase assay was performed using 
NF-κB reporter plasmid together with renilla 
luciferase plasmid for normalization. Detection of 
firefly luciferase and renilla luciferase expression 
was done using the dual luciferase assay detection 
kit (Promega, MA). 
Monocyte-derived dendritic cell differentiation 
and maturation - Elutriated monocytes were 
obtained from the Etablissement Français du Sang 
(EFS; Strasbourg, France). Monocytes were 
cultured in RPMI 1640 with Ultraglutamine 
(Lonza) supplemented with 10 µg/mL of 
gentamycin, 2 mM HEPES and 10% heat-
inactivated fetal calf serum. At day 0, cells were 
seeded at a density of 4 x 106 cells per well in a 6-
wells plate and differentiation into CD209-positive 
dendritic cells was induced by addition of 5 ng/mL 
of GM-CSFHuXp and 5 ng/mL of IL-4HuXp 
(Humanzyme, Chicago, IL). At day 5, when 
greater than 80% of the cells expressed CD209 
(data not shown), cells were incubated with the 
indicated stimuli in the presence or absence of 100 
µg/mL of polymyxin B (Fluka). After 24 h of 
culture, cells were harvested, washed with 2 mL of 
cold PBS and maturation maker expression was 
analyzed by flow cytometry. 
Flow cytometry analysis - Cells were stained in 
PBS containing 2% fetal calf serum at 4°C for 20 
min with the various antibodies used at 
concentration recommended by the manufacturer. 
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After two washes in PBS, cells were analyzed by 
flow cytometry with a Gallios flow cytometer 
(Beckman Coulter, CA). At least 10,000 events 
were acquired for each experiment and the data 
were processed with the Kaluza® Flow Analysis 
Software (Beckman Coulter, CA). 
Statistical analysis - FRET experiments were 
analyzed using one-way ANOVA with Tukey 
post-test, luciferase NF-κB and monocyte-derived 
dendritic cell maturation assays were analyzed 
using two-way ANOVA with Bonferroni post-test; 
using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, 
www.graphpad.com 
 
RESULTS 
CD40 dimerizes through the extracellular 
region - In order to define the oligomerization 
state of CD40 in the absence of ligand, HEK cells 
stably transfected with full length wt CD40 were 
chemically cross-linked with the non-permeable 
reagent BS3. Western blot analysis revealed that a 
portion of CD40, migrating at ~45 kDa, shifted to 
a dimer of ~90 kDa in cross-linked cell lysates 
(Fig. 1A). Some CD40 dimer was also observed in 
the B cell lymphoma BJAB cell line that expresses 
endogenous CD40 (Fig. 1A). To define the 
contribution of the extracellular region to 
dimerization, soluble CD40 fused to the non-
oligomerizing Myc and His tags was produced in 
mammalian cells. This soluble CD40 bound 
CD154 in a surface plasmon resonance assay (data 
not shown). Under denaturing SDS-PAGE, soluble 
CD40 migrated as a band of ~36 kDa under both 
reducing and non-reducing conditions, but the 
same protein eluted with an apparent molecular 
weight of ~72 kDa from a size exclusion 
chromatography column, suggesting that it may 
form roughly globular dimers (Fig. 1B). Although 
glycosylation interfered with ionization of soluble 
CD40 in native mass spectrometry (Suppl. Fig. 1), 
the deglycosylated protein behaved well in this 
assay which allowed detection of two peaks at 
masses of 23.94 and 47.86 kDa, corresponding 
relatively closely to expected theoretical values for 
the non glycosylated monomeric (23.4 kDa) and 
dimeric (46.7 kDa) CD40 (Fig. 1C). Taken 
together, these results indicate that at least a 
fraction of CD40 can self-assemble in the absence 
of ligand, most probably as a non-covalent 
homodimer. 
CD40-CRD1 mediates self-interaction of 
CD40 - In order to define the site required for 
CD40 self-assembly, we first constructed a model 
of a CD40 dimer based on the structures of the 
parallel TNFR1 dimer (1NCF) and ligand-bound 
CD40 (3QD6). The rational was that a) the 
structure of monomeric (liganded) and dimeric 
(unliganded) TNFR1 differ strongly in CRD1, 
suggesting that this domain is important for self-
assembly (Suppl. Fig. 2A), b) lymphotoxin α-
TNFR1 is the closest available crystal structure to 
CD40-CD40L [15], and given that c) CRD1 and 2 
of TNFR1 and CD40 superimpose with a Cα root 
mean square deviation of 1.05 Å, chances of 
getting a relevant model were good (Suppl. Fig. 
2B). 
The model suggested the involvement of the 
CRD1 domain in CD40 self-assembly, with an 
important contribution of Lys29 (Fig. 2A). We 
therefore generated full-length CD40 constructs 
with mutation K29A, K29E or with mutations 
predicted to disrupt folding of the first A1 sub-
domain (C26Q) or of the entire CRD1 (triple 
cysteine mutant C37G-C38G-C41G: mutC), or 
lacking CRD1 but retaining the signal peptide 
(CD40ΔCRD1) (Fig. 2B). With the exception of 
the K29A and K29E mutants, all other untagged or 
EYFP-tagged CD40 CRD1 mutants were all 
retained in the endoplasmic reticulum, failed to 
efficiently reach the cell surface and did not 
respond to exogenously added CD40L (Fig. 2C; 
Suppl. Fig. 3, 4 and 5A), indicating that CD40 is 
sensitive to mutations affecting normal folding of 
its CRD1. In line with these results, steered 
molecular dynamic simulation showed strong local 
perturbations in CD40-CRD1 in the case of C26Q 
and mutC mutations and strong local perturbations 
in CD40-CRD2 in the case of the delta CRD1 
construct (Supp. Fig. 5B). As mentioned above, 
the CD40 dimer model suggested a contribution of 
Lys29 in receptor dimerization, and it is 
noteworthy that this residue is conserved in human 
and mouse CD40. In silico mutation of this residue 
to an alanine increased the interaction energies 
from -361 kcal/mol to -219 kcal/mol, highlighting 
its importance in receptor dimerization. We also 
introduced the mutation K29E in order to obtain a 
stronger effect by charge repulsion. Neither K29A 
nor K29E mutations alter the surface expression of 
CD40 (Fig. 2D). Furthermore, CD40L induced 
NF-κB activity was similar in wt CD40 cell line 
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when compared with the mutant cell lines K29A 
and K29E (Fig. 2E). Under the same conditions, 
no activity was observed in CD40 cell line lacking 
the intracellular domain (CD40-ΔICD). However, 
the ability of the CD40 K29A or K29E mutants to 
produce FRET signals with either themselves or 
with wt CD40 was reduced by about 50%, 
supporting the notion that Lys29 is involved in 
CRD1-mediated dimerization of CD40 (Fig. 3A). 
Finally, chemical cross-linking of untagged mutant 
or wt CD40 showed a marked reduction of dimeric 
species at the cell surface when using both mutant 
receptors in comparison with wt CD40 (Fig.3B). 
Recombinant CD40-CRD1 binds to CD40 - 
Although the isolated CD40-CRD1 was poorly 
secreted in HEK cells, it was successfully 
produced in a prokaryotic expression system with 
human-compatible tRNAs and enhanced ability to 
form disulfide bridges. CD40-CRD1 was also 
expressed with the K29A, K29E and CRD1-
disrupting mutations C26Q or mutC (Fig. 4A). All 
CRD1 molecules migrated on SDS-PAGE with an 
apparent molecular weight of ~16 KDa despite 
their theoretical molecular weight of ~8 KDa. 
Wild type CD40-CRD1 bound to the extracellular 
domain of CD40 with a KD of 5.7 x 10-7 M (kon 
2.04 x 103 M-1s-1 and koff 1.16 x 10-3 s-1), as 
determined by surface plasmon resonance 
analysis, whereas no binding was detected for both 
cysteine mutants (Fig. 4B and Suppl. Fig. 6). 
These data show the importance of an adequate 
CRD1 folding for binding to CD40. Of note, using 
surface plasmon resonance, the active 
concentration of CD40-CRD1 was estimated to be 
4.7 % of the total protein. In all experiments, the 
mentioned concentration of CD40-CRD1 is that of 
the active protein. The concentration of CRD1 
mutants was estimated also as 4.7 % of the total 
protein although it was not possible to estimate its 
active fraction because there are no detectable 
binding to CD40. 
Recombinant CD40-CRD1 induces a mild ligand-
like activity and potentiates CD40L signals - As 
expected, an overnight stimulation of CD40-
expressing cells with CD40L activated the NF-κB 
transcription factor and induced expression of a 
NF-κB luciferase reporter gene (Fig. 4C). 
Surprisingly, soluble CD40-CRD1 showed a weak 
agonistic activity on wt CD40-expressing HEK 
cells, but not on cells expressing  CD40-K29A, 
CD40-K29E or CD40 lacking the intracellular 
domain (CD40-ΔICD) (Fig. 4C). Furthermore, wt 
CRD1, but not the mutants, potentiated CD40L-
induced NF-κB activation by up to 2-fold, with an 
IC50 of about 1.5 ± 0.5 µg/ml (Fig. 4D). In line 
with the observation that wt CD40-CRD1 could 
induce NF-κB activity in cells expressing wt 
CD40, but not in cells expressing mutant CD40, 
recombinant mutant CD40-CRD1 proteins were 
unable to increase CD40L activity in wt CD40 
HEK cells. Because the CRD1 of CD40 does not 
interact with CD40L in the crystallographic 
structure of the CD40-CD40L complex [15], we 
believe that the observed signal potentiation 
results from independent effects of CD40-CRD1 
and CD40L on membrane CD40. 
 
When human monocyte-derived dendritic cells 
(MDDC) from different donors were treated with 
increasing concentrations of wt CD40-CRD1, the 
surface maturation markers CD86 and HLA-DR 
were up-regulated (Fig. 5). This effect occurred in 
the presence of the LPS inhibitor polymyxin B 
[19], making it unlikely that it was endotoxin-
mediated. Moreover, CD40-CRD1 K29E was 
markedly less potent than its wt counterpart at 
stimulating dendritic cells. Unlike CD40L, wt 
CD40-CRD1 taken alone failed to up-regulate the 
activation marker CD83, suggesting that it is less 
potent than CD40L (Fig. 5). When dendritic cells 
were treated simultaneously with wt CD40-CRD1 
and CD40L, a modest potentiation of CD40L-
induced activation was observed at low doses of 
recombinant CD40-CRD1 (Suppl. Fig. 7A and B).  
Taken together, our results suggest that the 
CRD1 of CD40 can increase CD40-dependent 
signals in target cells, alone or in cooperation with 
CD40L. 
 
DISCUSSION 
Although it is well established that CD154 
(CD40L) assembles as a trimer, not much research 
has been conducted on CD40 oligomerization 
before ligand engagement and on the potential 
functional effect of this oligomerization. Reports 
from Mourad’s group suggested that CD40 at the 
cell surface exist as disulfide-linked dimers and 
that disulfide-linked homodimerization was 
increased by CD40L [20-22]. However, all 
cysteine residues in the extracellular region of 
CD40 and other crystallized TNFR family 
members are engaged in intra-chain disulfide 
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bridges, making it unlikely that CD40 would 
dimerize through inter-chain extracellular covalent 
bonds. 
In the present study, we show that CD40 can 
self-assemble at the cell surface in a non covalent 
manner, probably as dimers. Soluble CD40 also 
dimerizes, suggesting that the extracellular domain 
plays an important role in dimer formation. In 
addition, in silico modelization and site-directed 
mutagenesis confirmed the role of CD40-CRD1 in 
receptor-receptor interactions. Until now, only 
TNFR1 and DcR3 have been crystallized as 
ligand-free receptors. TNFR1 crystallized as both 
parallel and anti-parallel dimers [6]. The parallel 
dimer was stabilized by interactions involving 
CRD1 and exposed fully accessible TNF binding 
sites in CRD2 and CRD3. In contrast, the anti-
parallel dimer was stabilized by interactions 
involving CRD1 and CRD2 that occluded the TNF 
binding sites. Parallel TNFR dimers are favoured 
at neutral pH, while anti-parallel TNFR dimers are 
favoured at acidic pH [7]. This observation led to 
the hypothesis that parallel dimers may occur at 
the cell surface and could serve to create an 
activation network in the presence of ligand, in 
contrast to anti-parallel dimers that may form upon 
acidification of endocytic vesicles and release the 
ligand from the complex [7]. Unliganded DcR3 
was also crystallized as parallel dimers, with the 
main contact area in CRD1 and 4, and an 
accessible ligand binding site to its ligand TL1A 
[9]. Sedimentation equilibrium analyses of DcR3 
showed weak self-association, with an estimated 
equilibrium dissociation constant greater than 2.4 
x 10-3 M, a low value if we consider that the 
physiological concentration of this soluble 
receptor is in the range of 10-12 pM [23]. 
Interestingly, the CRD1-CRD1 interaction surface 
modelled for CD40 in our study superimposed 
relatively well with the interaction surface found 
between the CRD1 of the TNF receptor HVEM 
and the immunomodulatory protein BTLA in the 
HVEM – BTLA complex [24]. Therefore, a CRD1 
seems to use the same interface to interact with 
another CRD1 (as in the TNFR1 dimer) or with a 
regulatory protein. The CRD1 could therefore be 
considered as an interaction domain that regulates 
receptor activity by interacting either with itself or 
with other proteins such as BTLA. 
Using surface plasmon resonance, an 
equilibrium dissociation constant of 5.7 x 10-7 M 
was determined for the interaction between CD40 
and recombinant CD40-CRD1. Although this 
equilibrium constant is rather low, it may still be 
relevant since local protein concentrations on the 
cell membrane can be high, especially in some 
micro-domains, and since other interaction sites 
outside CRD1 may also participate to 
dimerization. These results raise the question of 
whether the active form of the receptor is the 
dimeric or the monomeric form, and whether 
receptor dimers persist after ligand engagement. 
Further analyses are warranted to address these 
questions.  
The CRD1 of TNFR1 fused to glutathione-S-
transferase as been previously described as an 
inhibitor of TNFR1-mediated signalling [25]. This 
molecule could block the effects of TNF in vitro 
and was shown to inhibit arthritis in mice [25]. 
Unfortunately, this study was not designed to 
address the molecular basis of these effects, nor 
did it test the potential impact of glutathione-S-
transferase-induced dimerization on CRD1 
activity. In the case of Fas, the study of dominant-
interfering mutations associated with autoimmune 
lymphoproliferative syndrome (ALPS) revealed 
that Fas CRD1 was fully preserved in all 
dominant-interfering mutations, including 
mutations that truncate Fas after 57 or 62 amino 
acids of the mature Fas protein and that would be 
unable to bind FasL  [10]. In addition, deletion of 
CRD1 in dominant-negative inhibitory receptors 
restored susceptibility to FasL-induced apoptosis, 
indicating that mutant proteins must physically 
interact with wild type proteins to create a non-
functional complex. Although the phenotype of 
patients provide strong genetic evidence for a 
dominant-negative function of the N-terminal 
portion of Fas, results obtained with N-terminal 
Fas deletion mutants must be taken with caution in 
view of our results demonstrating that CRD1 
disruption prevents CD40 surface expression. At 
least for CD40, N-terminal truncation or severe 
perturbations of CRD1 structures are not 
appropriate to study CRD1 function. In any case, 
the studies mentioned above indicate that the N-
terminal portions of TNFR1 and Fas taken alone 
antagonize receptor signalling. 
Because of the described inhibitory activity of 
TNFR1 and Fas CRD1, the ability of recombinant 
CD40-CRD1 to induce a weak CD40 activation 
rather than an inhibition of NF-κB signalling was 
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unexpected. A gross artefact can probably be 
excluded as NF-κB activation was CD40-
dependent, and as CRD1 disruption mutants were 
ineffective. The agonist activity of CD40-CRD1 
could be explained in several ways: a) if CD40 is 
inhibited by dimerization, then recombinant CRD1 
may activate CD40 by disrupting the dimers. b) 
recombinant CRD1 could oligomerize CD40 on 
the cell surface, inducing an agonist-like 
signalling, and c) recombinant CRD1 may induce 
conformational changes in the receptor similar to 
those induced by the ligand upon signal activation. 
Importantly, the agonist activity of CD40-CRD1 
was not restricted to cells overexpressing CD40, 
but was also observed in primary, monocyte-
derived dendritic cells. However, the observation 
that CD40-CRD1 was unable to induce the full set 
of activation markers in dendritic cells probably 
indicates a weak agonist activity compared to 
CD40L. 
Altogether, our result have revealed the ability 
of CD40 to self-assemble through its cysteine-rich 
domain 1 and the ability of recombinant CD40-
CRD1 to potentiate CD40L in HEK CD40 cells 
and to induce a ligand-like activity in human 
dendritic cells. Our data indicate that CD40 homo-
dimerization controls signalling, possibly by 
maintaining the receptor in a quiescent state, 
although further studies are needed to elucidate 
mechanisms mediating receptor activation. 
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FIGURE LEGENDS 
 
FIGURE 1. CD40 dimerizes through the extracellular region. 
Panel A. BJAB cells and stably transfected CD40 HEK cells where treated or not with the non permeable 
chemical crosslinker BS3. CD40 was then detected by western blotting with an anti-CD40 antibody. 
Panel B. The recombinant extracellular region of CD40 was analyzed by SDS-PAGE in the presence or 
absence of β-mercaptoethanol (left) and by size exclusion chromatography (right). 
Panel C. Native mass spectrometry analysis of the recombinant extracellular region of CD40. The protein 
was deglycosylated before native mass analysis. The insert shows a Western blot analysis of soluble 
CD40 before and after deglycosylation. 
 
FIGURE 2. CD40 CRD1 is required for normal surface expression. 
Panel A. Detail of the CD40 dimer model in the region of CRD1-CRD1 interaction, showing side chains 
of K29, D49 and W71.  
Panel B. Schematic representation of the CRD1 domain of CD40 with disulfide bridges highlighted. 
Mutations tested are indicated. 
Panel C. Flow cytometry analysis of HEK293 cells transfected with untagged WT or mutant CD40 
constructs. Staining was performed with an anti-CD40 antibody in permeabilized or non-permeabilized 
(surface) conditions. 
Panel D. Flow cytometry analysis of different CD40-HEK293 stable cell lines used in this study. Staining 
was performed with Fc-CD40L followed by anti-human Fc-PE. 
Panel E. Dose-response of CD40L in a NF-κB luciferase activity assay in different CD40-expressing 
HEK cell lines (CD40-wt, CD40-K29A, CD40-K29E and CD40-ΔICD). 
 
FIGURE 3. Mutations of lysine 29 disrupt CD40 self-assembly. 
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Panel A. Cytometric FRET analysis of CD40 interaction with either wt CD40, CD40-K29A or CD40-
K29E, using both ECFP and EYFP fusion combinations. (p<0.01, **). 
Panel B. CD40 stable cell lines (wt, K29A and K29E) were treated or not with the non permeable 
chemical crosslinker BS3. CD40 was then detected by western bloting with an anti-CD40 antibody. 
Densitometry analysis is shown on the right as a ratio between monomeric and dimeric receptors. NS: 
non-specific signal. 
 
FIGURE 4. Recombinant CD40-CRD1 binds to CD40 and potentiates CD40L activity. 
Panel A. Purified CD40-CRD1, CRD1-K29E, CRD1-K29A, CRD1-C6Q and CRD1-mutC (20 µg 
protein/lane) were resolved by SDS-PAGE and stained with Coomasie blue. 
Panel B. Biacore sensorgram of CD40-CRD1 binding to the entire extracellular domain of CD40. 
Panel C. Luciferase reporter assay for NF-κB activity in different CD40 HEK cell lines (CD40-wt, CD40-
K29A, CD40-K29E and CD40-ΔICD) treated with recombinant soluble CD40-CRD1. Untreated cells are 
shown on the left and Mega-CD40L stimulated cells are shown on the right. 
Panel D. Luciferase reporter NF-κB assay in HEK CD40 cell line treated with 500 ng/ml of CD40L and 
increasing concentrations of recombinant soluble CD40-CRD1, CRD1-K29A, CRD1-K29E, CRD1-C6Q 
and CRD1-mutC. (p<0.05, *; p<0.01, **; p<0.001, ***). 
 
FIGURE 5. Recombinant CD40-CRD1 induces maturation of human monocyte-derived dendritic cells. 
Panel A. CD14 positive cells (scattergram on the left) were cultured in the presence of IL-4 and GM-CSF 
for 5 days. Cells were then treated for 24 h with PBS (Vehicle), LPS (10 µg/mL) or LPS plus polymyxin 
B (100 µg/mL) (LPS+PMX) and analyzed for expression of activation markers CD86 and HLA-DR on 
CD209 positive cells. 
Panel B. Expression of maturation markers CD86, HLA-DR and CD83 (geo-mean, gMFI) was assessed 
after treatment with the indicated concentrations of recombinant wt CD40-CRD1 or CD40-CRD1 K29E  
in the presence of polymyxin B (100 µg/mL). Control treatments CD40L (200 ng/mL of Mega-CD40L) 
and LPS plus polymyxin B (100 µg/mL) (LPS+PMX) are also shown for each donor. Mean value with 
SEM of triplicates are shown (p<0.001, ***). Data is representative of two independent experiments 
performed on a total of three different donors. 
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